Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure--a subgroup analysis from the Trieste Cardiomyopathy Registry.
Aleksova A, Sabbadini G, Merlo M, Pinamonti B, Barbati G, Zecchin M, Bussani R, Silvestri F, Iorio AM, Stolfo D, Dal Ferro M, Dragos AM, Meringolo G, Pyxaras S, Lo Giudice F, Perkan A, di Lenarda A, Sinagra G. Aleksova A, et al. Among authors: pyxaras s. J Cardiovasc Med (Hagerstown). 2009 Sep;10(9):699-705. doi: 10.2459/JCM.0b013e32832bba35. J Cardiovasc Med (Hagerstown). 2009. PMID: 19474760
Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
Geraci S, Kawamoto H, Caramanno G, Ruparelia N, Capodanno D, Brugaletta S, Gori T, Nef H, Sabate M, Mehilli J, Lesiak M, Naber C, Di Mario C, Capranzano P, Wiebe J, Araszkiewicz A, Pyxaras S, Mattesini A, Münzel T, Tamburino C, Colombo A, Latib A. Geraci S, et al. Among authors: pyxaras s. JACC Cardiovasc Interv. 2017 Mar 27;10(6):560-568. doi: 10.1016/j.jcin.2016.12.013. Epub 2017 Mar 1. JACC Cardiovasc Interv. 2017. PMID: 28259663 Free article.
Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry.
Naganuma T, Colombo A, Lesiak M, Capodanno D, Gori T, Nef H, Caramanno G, Naber C, Di Mario C, Ruparelia N, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Kawamoto H, Pyxaras S, Mattesini A, Münzel T, Tamburino C, Latib A. Naganuma T, et al. Among authors: pyxaras s. Catheter Cardiovasc Interv. 2017 Jan;89(1):47-56. doi: 10.1002/ccd.26634. Epub 2016 Jul 14. Catheter Cardiovasc Interv. 2017. PMID: 27414021
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C. Capodanno D, et al. Among authors: pyxaras s. EuroIntervention. 2015 Feb;10(10):1144-53. doi: 10.4244/EIJY14M07_11. EuroIntervention. 2015. PMID: 25042421 Free article.
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
Ortega-Paz L, Capodanno D, Giacchi G, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S. Ortega-Paz L, et al. Among authors: pyxaras s. Catheter Cardiovasc Interv. 2017 Apr;89(5):812-818. doi: 10.1002/ccd.26674. Epub 2016 Aug 12. Catheter Cardiovasc Interv. 2017. PMID: 27515568
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score.
Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabaté M, Tamburino C, Brugaletta S. Ortega-Paz L, et al. Among authors: pyxaras s. EuroIntervention. 2017 Apr 20;12(17):2110-2117. doi: 10.4244/EIJ-D-16-00974. EuroIntervention. 2017. PMID: 28246060
Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry.
Capranzano P, Capodanno D, Brugaletta S, Latib A, Mehilli J, Nef H, Gori T, Lesiak M, Geraci S, Pyxaras S, Mattesini A, Münzel T, Araszkiewicz A, Caramanno G, Naber C, Di Mario C, Sabatè M, Colombo A, Wiebe J, Tamburino C. Capranzano P, et al. Among authors: pyxaras s. Catheter Cardiovasc Interv. 2018 Feb 15;91(3):444-453. doi: 10.1002/ccd.27388. Epub 2017 Oct 25. Catheter Cardiovasc Interv. 2018. PMID: 29068130
Procedural Impact of Advanced Calcific Plaque Modification Devices Within Percutaneous Revascularization of Chronic Total Occlusions.
Vadalà G, Mashayekhi K, Behnes M, Ayoub M, Gorgulu S, Werner GS, Kalay N, Avran A, Goktekin O, Garbo R, Jaroslaw W, Zaczkiewicz M, Arnez J, Pyxaras S, Christiansen EH, Gutiérrez-Chico JL, Maniscalco L, Madaudo C, Boudou N, Stojkovic S, Gasparini GL, Agostoni P, Diletti R, di Mario C, Bulum J, Galassi AR; EURO CTO Investigators. Vadalà G, et al. Among authors: pyxaras s. JACC Cardiovasc Interv. 2025 Jun 9;18(11):1376-1390. doi: 10.1016/j.jcin.2025.04.035. JACC Cardiovasc Interv. 2025. PMID: 40500006 Free article.
Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.
Roffi M, Landi A, Heg D, Frigoli E, Chalkou K, Chevalier B, Ijsselmuiden AJJ, Kastberg R, Komiyama N, Morice MC, Onuma Y, Ozaki Y, Peace A, Pyxaras S, Sganzerla P, Williams R, Xaplanteris P, Vranckx P, Windecker S, Smits PC, Valgimigli M; MASTER DAPT Investigators. Roffi M, et al. Among authors: pyxaras s. JACC Cardiovasc Interv. 2024 Nov 25;17(22):2664-2677. doi: 10.1016/j.jcin.2024.08.030. JACC Cardiovasc Interv. 2024. PMID: 39603779 Clinical Trial.
78 results